SAN DIEGO, June 5, 2013 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions, has filed a lawsuit in U.S. Federal Court, Southern District of California in San Diego, to stop infringement of ResMed patents.
ResMed filed the action against Chinese medical device manufacturer BMC Medical Co., Ltd. and its U.S. sales subsidiary, 3B Products, LLC, asserting patent infringement by:
ResMed further filed a request to add BMC to its pending International Trade Commission (ITC) case against Taiwanese manufacturer APEX to stop the importation and sales of these products in the United States.
The ITC case against APEX, filed March 27, 2013, also named Medical Depot, Inc., doing business as Drive Medical Design and Manufacturing, in the patent infringement case. On May 30, Drive Medical Design and Manufacturing filed papers stating that it is prepared to enter into a consent decree promising to stop importation and sales of the APEX products named in the ITC proceeding.
"ResMed has built its unique market differentiation by investing in superior technology and medical science-driven innovation for sleep-disordered breathing therapy," said ResMed global general counsel and chief administrative officer David Pendarvis . "We will continue to defend our proprietary technology by enforcing our patents."
ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.
Contacts:For News MediaFor the Finance and Investor CommunityGretchen GriswoldConstance BienfaitDirector, Global Corporate CommunicationsDirector, Investor RelationsO: 858-836-6789O: email@example.com@resmed.com
|SOURCE ResMed Inc.|
Copyright©2012 PR Newswire.
All rights reserved